Kinase News and Research

RSS

TSRI scientists identify key triggers of cancer-blocking mechanism in cells

Scientists at The Scripps Research Institute have identified key triggers of an important cancer-blocking mechanism in cells.

12 Jun 2013

Countrywide study in Germany deems PRRT as life-prolonging treatment for patients with NETs

Peptide-receptor radionuclide therapy has been a subject of growing research on neuroendocrine tumors, which take up residence in a variety of organs replete with nerve cells that respond to hormone signaling.

12 Jun 2013

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

ARIAD Pharmaceuticals, Inc. today announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors.

11 Jun 2013

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life issues that need to be addressed. Some of these issues include depression, fatigue, nausea and change of appearance.

11 Jun 2013

Researchers discover potential target for cancer-fighting drugs

As tumors grow, their centers are squeezed of oxygen. And so tumors must flip specific genetic switches to survive in these hypoxic environments.

10 Jun 2013

Research reveals how HIV triggers signal to kill infected immune cell

Untreated HIV infection destroys a person's immune system by killing infection-fighting cells, but precisely when and how HIV wreaks this destruction has been a mystery until now. New research by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, reveals how HIV triggers a signal telling an infected immune cell to die.

6 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

Researchers provide insights into potential therapeutic approaches to Down syndrome

University of Michigan researchers have determined how a gene that is known to be defective in Down syndrome is regulated and how its dysregulation may lead to neurological defects, providing insights into potential therapeutic approaches to an aspect of the syndrome.

6 Jun 2013

Research demonstrates need for development of new treatments for regeneration of nerve cells

Researchers at the University of Michigan have evidence that a single gene controls both halves of nerve cells, and their research demonstrates the need to consider that design in the development of new treatments for regeneration of nerve cells.

5 Jun 2013

Blocking MHCII action rescues nerve cells from Parkinson's disease mechanisms, researchers find

The same mechanism that lets the immune system mount a massive attack against invading bacteria contributes to the destruction of brain cells as part of Parkinson's disease, according to a study published online today in the Journal of Neuroscience.

5 Jun 2013

Study provides important details for recently identified target in lung adenocarcinoma

In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the gene RET.

4 Jun 2013

Researchers identify ways to inhibit function of key protein linked to stem cell-like behavior in CML

A research team led by the Duke-NUS Graduate Medical School in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia, making it possible to develop drugs that may extend the survival of these patients.

4 Jun 2013

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.

3 Jun 2013

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.

3 Jun 2013

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.

1 Jun 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Potential new treatment approaches for liver diseases

By discovering the new mechanism by which estrogen suppresses lipid synthesis in the liver, UC Irvine endocrinologists have revealed a potential new approach toward treating certain liver diseases.

24 May 2013

Study shows PDH enzyme plays a major role in regulation of oncogene-induced cellular senescence

An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence induced by the oncogene BRAF, which usually appears mutated in melanoma and other cancers.

22 May 2013

Findings suggest that a prosaposin-based drug could block metastasis spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer.

22 May 2013

Kinase News and Research

TSRI scientists identify key triggers of cancer-blocking mechanism in cells

Countrywide study in Germany deems PRRT as life-prolonging treatment for patients with NETs

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

Researchers discover potential target for cancer-fighting drugs

Research reveals how HIV triggers signal to kill infected immune cell

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Researchers provide insights into potential therapeutic approaches to Down syndrome

Research demonstrates need for development of new treatments for regeneration of nerve cells

Blocking MHCII action rescues nerve cells from Parkinson's disease mechanisms, researchers find

Study provides important details for recently identified target in lung adenocarcinoma

Researchers identify ways to inhibit function of key protein linked to stem cell-like behavior in CML

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Potential new treatment approaches for liver diseases

Study shows PDH enzyme plays a major role in regulation of oncogene-induced cellular senescence

Findings suggest that a prosaposin-based drug could block metastasis spread

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News